Janis Shute (0000-0002-6586-7583)

Personal information

No personal information available

Biography

Main research interests include;
Mechanisms of lung inflammation, tissue damage and repair in cystic fibrosis
Development of novel mucolytics and new therapeutic applications for heparin
Mechanisms of epithelial repair in asthma
Mechanisms of inflammatory cell recruitment and its pharmacological manipulation
Endothelial dysfunction in cystic fibrosis and the links between inflammatory markers and oxidative stress.

Activities

Collapse all

University of Portsmouth: Portsmouth, Hampshire, GB

2013 to present | Professor of Respiratory Pharmacology (Pharmacy and Biomedical Sciences)

Employment

Janis Shute

https://orcid.org/0000-0002-6586-7583

Personal information

Biography

Activities

Employment (6)

University of Portsmouth: Portsmouth, Hampshire, GB

University of Portsmouth: Portsmouth, Hampshire, GB

University of Southampton: Southampton, Hampshire, GB

University of Southampton: Southampton, Hampshire, GB

University of Southampton: Southampton, Hampshire, GB

University of Birmingham: Birmingham, West Midlands, GB

Education and qualifications (2)

University of Reading: Reading, Berkshire, GB

University of Reading: Reading, Berkshire, GB

Professional activities (4)

eBIO Medicine: London, GB

Cystic Fibrosis Canada: Toronto, Ontario, CA

Inflammation Research: Heidelberg, DE

Cystic Fibrosis Trust: London, GB

Funding (9)

The effect of collagen peptides on dermal fibroblast function

Reducing inflammation in cystic fibrosis lung disease by targeting expression of CFTR in the endothelium with a copper-tobramycin complex.

Coagulation factors and exacerbations of asthma.

Identification of agents with multiple favourable activities as potential treatments for cystic fibrosis.

Urinary biomarkers of asthma exacerbation

Glucose uptake by normal human neutrophils

Probing the physiological function of neutrophil elastase in normal human neutrophils using novel dendritic neutrophil elastase inhibitors.

Isolating a heparin-derived sequence to activate DNase I-a novel therapeutic approach to improve airway clearance, reduce infective exacerbations and facilitate delivery of inhaled drugs in cystic fibrosis

Novel intracellular neutrophil elastase inhibitors (NEIs) for the treatment of airway inflammation in cystic fibrosis.

Works (50 of 93)

Biomarkers of asthma.

INHALEd nebulised unfractionated HEParin for the treatment of hospitalised patients with COVID-19 (INHALE-HEP): Protocol and statistical analysis plan for an investigator-initiated international metatrial of randomised studies.

Nebulised heparin as a treatment for COVID-19: scientific rationale and a call for randomised evidence

Urinary fibrinopeptide-A as a predictive biomarker of exacerbation in asthma

Critical analysis of the utility of initial pleural aspiration in the diagnosis and management of suspected malignant pleural effusion

Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) in human lung microvascular endothelial cells controls oxidative stress, reactive oxygen-mediated cell signaling and inflammatory responses

Circulating biomarkers of antioxidant status and oxidative stress in people with cystic fibrosis: a systematic review and meta-analysis

The implications of dysglycaemia on aerobic exercise and ventilatory function in cystic fibrosis

Reply to Askew and Green.

Reply to Cooper

Targeting MMP-13 in bronchial epithelial repair

Cardiopulmonary exercise testing with supramaximal verification produces a safe and valid assessment of V̇O2max in people with cystic fibrosis

Effects of collagen-derived bioactive peptides and natural antioxidant compounds on proliferation and matrix protein synthesis by cultured normal human dermal fibroblasts

Therapeutic use of heparin and derivatives beyond anticoagulation in patients with bronchial asthma or COPD

WS08.3 Combined ramp and supramaximal cardiopulmonary exercise testing for individuals with cystic fibrosis

Inhaled nebulised unfractionated heparin improves lung function in moderate to very severe COPD: a pilot study

Delivery device and formulation

Physiological and biological predictors of length of stay and recovery in adults with acute asthma

A randomised double-blind placebo-controlled trial of the effect of inhaled heparin on lung function, hyperinflation and exercise capacity in patients with COPD

The effects of tobramycin on pulmonary fibroblast function

Heparin derivatives for the targeting of multiple activities in the inflammatory response.

Women in science and technology

Altered colonic mucosal availability of n-3 and n-6 polyunsaturated fatty acids in ulcerative colitis and the relationship to disease activity

Anti-inflammatory effects of tobramycin and a copper–tobramycin complex with superoxide dismutase-like activity

Cytokine mucosal expression in ulcerative colitis, the relationship between cytokine release and disease activity

N-acetyl-L-cysteine protects against inhaled sulfur mustard poisoning in the large swine

A copper–hydrogen peroxide redox system induces dityrosine cross-links and chemokine oligomerisation

Active ulcerative colitis is associated with altered fatty acid precursor availability for the eicosanoid synthetic pathway

Up-regulation of the extrinsic coagulation pathway in acute asthma - a case study

Alveolar inflammation in cystic fibrosis

The role of protease-activated receptors PAR-1 and PAR-2 in the repair of 16HBE 14o-epithelial cell monolayers in vitro

Coagulation factors in the airways in moderate and severe asthma and the effect of inhaled steroids

Macrorheology of cystic fibrosis, chronic obstructive pulmonary disease & normal sputum

Human mid-gestation amniotic fluid contains interleukin-16 bioactivity

Cospray-dried unfractionated heparin with L-leucine as a dry powder inhaler mucolytic for cystic fibrosis therapy

The spray drying of unfractionated heparin: optimization of the operating parameters

Airway remodelling in children with cystic fibrosis

Unfractionated heparin reduces the elasticity of sputum from patients with cystic fibrosis

Actin limits enhancement of nanoparticle diffusion through cystic fibrosis sputum by mucolytics

Fibrin formation by wounded bronchial epithelial cell layers in vitro is essential for normal epithelial repair and independent of plasma proteins

Inhaled heparin in cystic fibrosis

Inflammatory responses to the occupational inhalation of metal fume

MMP-9, TIMP-1 and inflammatory cells in sputum from COPD patients during exacerbation

Endothelial activation and increased heparan sulfate expression in cystic fibrosis

Epithelial expression and release of FGF-2 from heparan sulphate binding sites in bronchial tissue in asthma

Effect of treatment with dornase alpha on airway inflammation in patients with cystic fibrosis

Free secretory component from cystic fibrosis sputa displays the cystic fibrosis glycosylation phenotype

Pharmacological properties of raspberry leaf extracts in vitro

Combination therapy for respiratory disorders